Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center
Background: CT-P13, the first biosimilar monoclonal antibody to infliximab (IFX), has been confirmed to be efficacious in inducing remission in inflammatory bowel diseases (IBD). The aim of this study was to evaluate the long-term efficacy and safety of CT-P13 therapy in Crohn’s disease (CD) and ulc...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2017
|
| Sorozat: | EXPERT OPINION ON BIOLOGICAL THERAPY
17 No. 11 |
| doi: | 10.1080/14712598.2017.1363885 |
| mtmt: | 3269325 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/12187 |